Nuwellis Inc Stock Price, News & Analysis

Nuwellis, Inc. (NASDAQ:NUWE) announced the pricing of an underwritten public offering of 3,483,120 shares at $2.50 each, generating approximately $8.7 million before expenses. An additional 522,468 shares may be purchased by underwriters within 45 days. The proceeds will support general corporate purposes, particularly commercialization efforts. The offering is part of a shelf registration statement filed with the SEC. Closing is expected on or about September 17, 2021, subject to customary conditions.

Nuwellis, Inc. (NASDAQ:NUWE) announced plans for an underwritten public offering of its common stock, with the possibility for underwriters to purchase an additional 15% of shares. Proceeds from the offering will be used for general corporate purposes, enhancing commercialization efforts. The offering is subject to market conditions, and no assurance can be made regarding completion or terms. Ladenburg Thalmann & Co. Inc. is the sole book-running manager for the offering, which follows the company’s effective shelf registration statement.

Nuwellis, Inc. (NASDAQ: NUWE) announced the approval of an equity award under its 2021 Inducement Plan for a new employee, effective September 13, 2021. The award includes an option to purchase 5,965 shares at an exercise price of $4.02, reflecting the stock's closing price on the grant date. The option vests over four years, with 25% vesting after the first year. Nuwellis specializes in medical devices, focusing on the Aquadex SmartFlow® system for treating fluid overload in patients. This award complies with NASDAQ Listing Rule 5635(c)(4), necessitating public notice of non-stockholder approved equity awards.

Nuwellis, Inc. (NASDAQ: NUWE) announced its participation in two upcoming investor conferences. Nestor Jaramillo Jr. and George Montague will represent the company at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 AM ET, and at the Lake Street Capital Markets 5th Annual Best Ideas Growth Conference on September 14, 2021, at 11:00 AM ET. The webcasts will be accessible on Nuwellis’ Investor Relations website, with a replay available for 90 days post-event.

Nuwellis focuses on solutions for patients with fluid overload, featuring the Aquadex SmartFlow system.

Nuwellis, Inc. (NASDAQ: NUWE) announced on August 24, 2021, that independent directors approved equity awards for four new hires under the 2021 Inducement Plan. These awards, as per NASDAQ Listing Rule 5635(c)(4), consisted of options to purchase a total of 42,345 shares of common stock at an exercise price of $4.57 per share, equal to the closing price on the grant date. The options have a ten-year term, vesting over four years, contingent on continued employment. Nuwellis focuses on the Aquadex SmartFlow system for treating fluid overload in patients.

Nuwellis, Inc. (Nasdaq: NUWE) reported record quarterly revenue of $2.5 million for Q2 2021, marking a 35% increase from the previous year. This is the sixth consecutive quarter of double-digit growth, fueled by strong demand for capital equipment and consumables. Notable leadership additions include George Montague as CFO and Neil Ayotte as Senior VP. The company received a Category III CPT code for therapeutic ultrafiltration, effective January 1, 2022. Despite a net loss of $4.7 million, cash reserves remain strong at $24 million with no debt.

Nuwellis (Nasdaq: NUWE) announced plans to develop a pediatric continuous renal replacement therapy (CRRT) device aimed at critically ill children with kidney failure. Supported by a $1.7 million NIH grant, this partnership with Koronis Biomedical Technologies will enhance treatment options for small patients. The device will address limitations in current therapies by improving functionality and reducing complications. The Aquadex SmartFlow® system is already recognized for its benefits in pediatric care, setting the stage for this innovative product to meet urgent medical needs.

Nuwellis, Inc. (NASDAQ: NUWE) will announce its second quarter 2021 financial results on August 10, 2021, at 9:00 AM ET. Following the release, management will host a conference call and webcast to discuss the company's performance and provide a business overview. Interested parties can access the live discussion via the Nuwellis Investors page or by phone. The company specializes in developing the Aquadex SmartFlow® system for ultrafiltration therapy, aimed at helping patients with fluid overload.

Nuwellis announces the issuance of a new Category III CPT code (0692T) for Therapeutic Ultrafiltration, effective January 1, 2022. This code aims to enhance reimbursement for providers using the Aquadex system to treat fluid overload in patients. The code's approval, following validation by the American Medical Association, supports the accessibility of this life-saving therapy. Nuwellis' CEO emphasizes the importance of this milestone for patient access and provider adoption, potentially improving treatment outcomes across the healthcare system.